NeOnc Technologies said its intranasal NEO100 met the primary endpoint in a Phase 2a study in recurrent IDH1-mutant high-grade glioma. The company reported six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark, with a reported p-value of 0.0047. NeOnc also disclosed overall survival and durability metrics, including median overall survival of 26.09 months and 86.7% of patients alive at six months. Within the small, open-label 24-patient cohort, the company noted that five patients remained on treatment at the time of analysis and that one patient stayed progression-free for roughly 19 months. Oncology investors will likely focus on the next step: NeOnc said it plans to request a Type B meeting with the U.S. FDA to discuss a registrational development path. The company emphasized that the results are early-stage and not a substitute for larger, controlled trials. If the signal replicates, an intranasal approach could broaden practical access in glioma care settings where delivery logistics and tumor biology are major constraints.